The use of recombinant factor VIIa in liver diseases

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 5, 2008, Pages 341-348

  Franchini, Massimo ^a,b   Montagnana, Martina ^a   Targher, Giovanni ^a   Zaffanello, Marco ^a   Lippi, Giuseppe ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b OSPEDALE POLICLINICO   (Italy)

Author keywords

Bleeding; Liver disease; Recombinant activated factor VII

Indexed keywords

ACENOCOUMAROL; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 7; DESMOPRESSIN; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP;

BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSFIBRINOGENEMIA; ESOPHAGUS VARICES; FIBRINOGEN DEFECT; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HUMAN; HYPERFIBRINOLYSIS; HYPOFIBRINOLYSIS; INVASIVE PROCEDURE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER COAGULOPATHY; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; OPEN STUDY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SURGICAL TECHNIQUE; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K DEFICIENCY;

BLOOD COAGULATION DISORDERS; CHRONIC DISEASE; FACTOR VIIA; GASTROINTESTINAL HEMORRHAGE; HEMOSTATICS; HUMANS; LIVER CIRRHOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 67649566434     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32830496a7     Document Type: Review

References (94)

1. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19:163-176.
2. Nègrier C, Lienhart A. Overall experience with NovoSeven. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1):19-24.
3. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7:408-413.
4. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin Thromb Hemost 2001; 27:373- 383.
5. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42:114-124.
6. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93:1027-1035.
7. Uhlmann EJ, Eby CS. Recombinant activated factor VIII for nonhemophiliac bleeding patients. Curr Opin Hematol 2004; 11:198-204.
8. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44:1325-1331.
9. Ghorashian S, Hunt BJ. 'Off-license' use of recombinant activated factor VII. Blood Rev 2004; 18:245-259.
10. Mathew P. The use of rFVIIa in nonhaemophilia bleeding conditions in paediatrics. Thromb Haemost 2004; 92:738-746.
11. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in nonhaemophiliac patients. Pathophysiol Haemost Thromb 2002; 32 (Suppl 1):41-46.
12. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104:3858-3864.
13. Macphail S,TalksK.Massive postpartum haemorrhage and management of disseminated intravascular coagulation. Curr Obstetr Gynaecol 2004; 14:123-131.
14. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 41:431-439.
15. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007; 114:8-15.
16. Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis 1996; 16:403-414.
17. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22:83-96.
18. Vardareli E, Saricam T, Demirustu C, Gulbas Z. Soluble P selectin levels in chronic liver disease: relationship to disease severity. Hepatogastroenterology 2007; 54:466-469.
19. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000; 14 (Suppl D):60D-66D.
20. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12:7725-7736.
21. Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005; 100:1311-1316.
22. Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond) 2000; 99:207-214.
23. Koruk M, Onuk MD, Akçay F, Savas MC. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology 2002; 49:1645- 1648.
24. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113:590-595.
25. Cowan DH. Effect of alcoholism on hemostasis. Semin Hematol 1980; 17:137-147.
26. de Almeida AJ, Campos-de-Magalhães M, Brandão-Mello CE, de Oliveira RV, Yoshida CF, Lampe E. Detection of hepatitis C virus in platelets: evaluating its relationship to viral and host factors. Hepatogastroenterology 2007; 54:964-968.
27. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37:1267-1276.
28. Feistauer SM, Penner E, Mayr WR, Panzer S. Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 1997; 25:1343-1345.
29. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, Kuwana M. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007; 22:112-118.
30. Marra F, Riccardi D, Melani L, Spadoni S, Galli C, Fabrizio P, et al. Effects of supplementation with unsaturated fatty acids on plasma and membrane lipid composition and platelet function in patients with cirrhosis and defective aggregation. J Hepatol 1998; 28:654-661.
31. Laffi G, Marra F, Gresele P, Romagnoli P, Palermo A, Bartolini O, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992; 103:641-646.
32. Ordinas A, Maragall S, Castillo R, Nurden AT. A glycoprotein I defect in the platelets of three patients with severe cirrhosis of the liver. Thromb Res 1978; 13:297-302.
33. Watanabe M, Shiraishi K, Itakura M, Matsuzaki S. Relationship between platelet membrane lipid compositions and platelet aggregability in alcoholic liver disease. Alcohol Clin Exp Res 1998; 22 (3 Suppl):97S- 102S.
34. 4-induced cirrhotic rat liver. J Hepatol 2003; 39:200-207.
35. Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut 2004; 53:877-883.
36. Federico A, Filippelli A, Falciani M, Tuccillo C, Tiso A, Floreani A, et al. Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: in vivo and in vitro studies. World J Gastroenterol 2007; 13:3677-3683.
37. Kelly DA, Tuddenham EG. Haemostatic problems in liver disease. Gut 1986; 27:339-349.
38. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91:267- 275.
39. Fimognari FL, De Santis A, Piccheri C, Moscatelli R, Gigliotti F, Vestri A, et al. Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med 2005; 146:238- 243.
40. Fair DS, Marlar RA. Biosynthesis and secretion of factor VII, protein C, protein S, and the Protein C inhibitor from a human hepatoma cell line. Blood 1986; 67:64-70.
41. Blanchard RA, Furie BC, Jorgensen M,Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305:242-248.
42. Cordova C, Musca A, Violi F, Alessandri C, Vezza E. Improvement of some blood coagulation factors in cirrhotic patients treated with low dosis heparin. Scand J Haematol 1982; 29:235-240.
43. Hallen A, Nilsson IM. Coagulation studies in liver disease. Thromb Diath Haemorrh 1964; 11:51-63.
44. vanDeWater L, Carr JM, Aronson D, McDonagh J. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. Blood 1986; 67:1468-1473.
45. Hilbenbrand P, Parbhoo SP, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 1974; 15:83.
46. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96:1581-1586.
47. GreenG, ThomsonJM, Dymock IW, PollerL.Abnormal fibrin polymerization in liver disease. Br J Haematol 1976; 34:427-439.
48. van Wersch JW, Russel MG, Lustermans FA. The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis. Eur J Clin Chem Clin Biochem 1992; 30:275-279.
49. Leebeek FWG, Kluft C, Knot EAR, de Maat MPM, Wilson JHP. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101:1382- 1390.
50. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Critical Care 2005; 9 (Suppl 5): S15-S24.
51. Lisman T, De Groot PHG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1:1138-1139.
52. van't Veer C, Mann KG. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemost 2000; 26:367-372.
53. Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1:1158-1160.
54. Butenas S,Brummel KE, Paradis SG, Mann KG. Influenceof factor VIIa and phospholipids on coagulation in 'acquired' hemophilia. Arterioscler Thromb Vasc Biol 2003; 23:123-129.
55. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542-547.
56. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994; 78:545-554.
57. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1):S69-S74.
58. ErhardtsenE,Nony P,Dechavanne M, Ffrench P,Boissel JP, HednerU.The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9:741-748.
59. Deveras RA, Kessler CM. Recombinant factor VIIa (rF-VIIa) successfully and rapidly corrects the excessively high international normalized ratios (INR) and prothrombin times induced by warfarin [abstract]. Blood 2000; 96:638a.
60. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Int Med 2002; 137:884-888.
61. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930-1937.
62. Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not brolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002; 35:616-621.
63. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46:919-933.
64. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 2004; 39:592-598.
65. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001; 10:1081-1085.
66. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, Gomez-Parra M, Argü elles Arias F, Guerrero-Aznar MD, et al. Recombinant activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clinical Gastroenterol Hepatol 2004; 2:78-84.
67. Bosch J, Thabut D, Bendtsen F. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127:1123-1130.
68. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43:1711-1716.
69. Marti-Carvajal AJ, Salanti G, Marti-Carvajal PJ. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases. Cochrane Database Syst Rev 2007:CD004887.
70. Shami VM, Caldwell SH, Hespendeide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138-143.
71. Brown JB, Emerick KM, Brown DL, Whitington PF, Alonso EM. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003; 37:268-272.
72. Lodge JPA, Jonas S, Oussoultzoglou E, Malagó M, Jayr C, Cherqui D, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anestesiology 2005; 102:269-275.
73. Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191:245-249.
74. Carreno V, Messner M, Arrieta J. The effect of recombinant factor VIIa (NovoSeven) on haemorrhage following dental surgery in patients with liver cirrhosis - a randomised placebo controlled study. Thromb Haemost 2001; (Suppl. ISTH XVIII Congress):P2612.
75. Hoffman M. Successful use of recombinant activated factor VII (NovoSeven) in controlling severe intra-abdominal bleeding after liver needle biopsy. Thromb Haemost 2002; 87:346-347.
76. Pasi J, Burroughs AK. Correction of both prothrombin time and primary hemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol 1999; 31:747-750.
77. Kositchaiwat C, Chuansumrit A. Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP). Thromb Haemost 2001; 86:1125- 1126.
78. Carvalho A, Leitao J, Louro E, Maia R, Geraldes C, Ventura C, et al. Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients. Rev Esp Enferm Dig 2002; 94:280-285.
79. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123:118-126.
80. Porte RJ, Caldwell SH. The role of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11:872-874.
81. Gibbs NM. The place of recombinant activated factor VII in liver transplantation. Int Anasthesiol Clin 2006; 44:99-110.
82. Kalicinski P, Kaminski A, Drewniak T, Ismail H, Szymczak M, Markiewicz M, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31:378-379.
83. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001; 71:402-405.
84. Surudo T, Wojcicki M, Milkiewicz P, Czuprynska M, Lubikowski J, Jarosz K, et al. Rapid correction of prothrombin time after low-dose recombinant factor VIIa in patients undergoing orthotopic liver transplantation. Transplant Proc 2003; 35:2323-2325.
85. Meijer K, Hendriks HGD, de Wolf JTM, Klompmaker IJ, Lisman T, Hagenaars AA, et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2003; 14:169-174.
86. Niemann CU, Behrends M, Quan D, Eilers H, Gropper MA, Roberts JP, et al. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores. Transf Med 2006; 16:93-100.
87. Kalicinski P, Markiewicz M, Kamiński A, Laniewski P, Ismail H, Drewniak T, et al. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation. Pediatr Transplant 2005; 9:299-304.
88. Planinsic RM, van der Meer J, Testa G, Grande L,Candela A, Porte RJ, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplant 2005; 11:895-900.
89. Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, et al., rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11:973-979.
90. Pugliese F, Ruberto F, Summonti D, Perrella S, Cappannoli A, Tosi A, et al. Activated recombinant factor VII in orthotopic liver transplantation. Transplant Proc 2007; 39:1883-1885.
91. Akyildiz M, Turan I, Ozutemiz O, Batur Y, Ilter T. A cerebrovascular event after single-dose administration of recombinant factor VIIa in a patient with esophageal variceal bleeding. Dig Dis Sci 2006; 51:1647-1649.
92. Pavese P, Bonadona A, Beaubien J, Labrecque P, Pernod G, Letoublon C, et al. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005; 52:26-29.
93. Weiskopf RB. Recombinant-activated coagulation factor VIIa (NovoSeven): current development. Vox Sang 2007; 92:281-288.
94. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care 2006; 10:R120.